MazelMan, I have never seen such warnings or safety type warnings with Bavituximab like this warning below for Opdivo. I would be very surprised if oncologists start being asked the tough questions and since the President of ESMO believes that better results will likely be found/expected from Immuno-Oncology trials, I believe that Bavituximab is the answer and Opdivo should probably combine with Bavi as well if they want to reduce these risks below. I believe Opdivo "MUST" combine with Bavituximab if any of these risks/warnings to be reduced.
What I find interesting, is the President of ESMO - Rolf Stahel states SOC vs the paradigm treatments currently in trials and he sees/expects better results from the trials. Is it because we are exactly in that paradigm shift at this moment and PS Targeting on the verge of taking Big Pharma by surprise? I say yes.
-----
and again, why does Rolf Stahel say things like that above? ...maybe because he knows of the drugs that are reaching the market first are not in anyway have the MOA re: PS Targeting properties and has much more risk as seen below...